Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000137796
Ethics application status
Approved
Date submitted
1/02/2013
Date registered
5/02/2013
Date last updated
15/12/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Sedentary behaviour and memory functions
Scientific title
The acute effect of prolonged sitting with and without intermittent bouts of light physical activity on cognitive functions in overweight/obese adults.
Secondary ID [1] 281875 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cognitive decline 288259 0
Overweight/obesity 288297 0
Condition category
Condition code
Mental Health 288611 288611 0 0
Studies of normal psychology, cognitive function and behaviour
Diet and Nutrition 288640 288640 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This randomised crossover trial involves two single-day treatment conditions separated by a one week wash/out period. Intervention: Sitting + light-intensity activity bouts: Following an initial steady-state period (150 mins – initial 2 hours + 30 mins) of being seated, participants will complete a 3 min bout of light-intensity walking on the treadmill (level, firm surface, slow pace – 3.2 km/hr). They will then return to the seated position. This procedure will be repeated on another 9 occasions every 30 minutes. Total duration and intensity of activity: 30 minutes at light-intensity.
Intervention code [1] 286437 0
Lifestyle
Intervention code [2] 286462 0
Behaviour
Intervention code [3] 286463 0
Prevention
Comparator / control treatment
One day of prolonged sitting without activity breaks: Participants will sit quietly in a comfortable chair for a 7 hour period
Control group
Active

Outcomes
Primary outcome [1] 288763 0
Executive functions (selective attention, shifting and inhibition) assessed by Stroop test, Eriksen flanker task, Letter memory, and N-back.
Timepoint [1] 288763 0
Baseline, at 4 hours, and at 7 hours.
Primary outcome [2] 288764 0
Short-term memory (visuospatial working memory) assessed by Corsi blocks.
Timepoint [2] 288764 0
Baseline, at 4 hours and at 7 hours.
Primary outcome [3] 288765 0
Long-term memory assessed by an episodic association test.
Timepoint [3] 288765 0
Baseline, at 4 hours and after 7 hours.
Secondary outcome [1] 300926 0
Interstitial glucose level measured by a CGMS (continuous glucose monitoring system)
Timepoint [1] 300926 0
Countinuous measurements during 7 hours
Secondary outcome [2] 300927 0
Plasma level of brain-derived neurotrophic factor, BDNF.
Timepoint [2] 300927 0
Baseline, at 4 hours and at 7 hours.
Secondary outcome [3] 300928 0
Plasma level of interleukin-6, IL-6.
Timepoint [3] 300928 0
Baseline, at 4 hours, and at 7 hours.
Secondary outcome [4] 300929 0
Plasma levels of catecholamines (adrenaline and noradrenaline).
Timepoint [4] 300929 0
Baseline, at 4 hours, and at 7 hours.
Secondary outcome [5] 300930 0
Plasma level of cortisol.
Timepoint [5] 300930 0
Baseline, at 4 hours, and at 7 hours.

Eligibility
Key inclusion criteria
Inclusion criteria includes: overweight or obesity (body mass index (BMI) > 25 kg/m2, but < 40 kg/m2) and English-speaking.
Minimum age
45 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion is based on: pregnancy; employment in a non-sedentary occupation; currently watching < 3 hours of television per day; regularly engaged in moderate-intensity exercise = 150 min/week (‘sufficiently active’) for > 3 months; diabetes; use of lipid-lowering medication; known physical activity contraindications, major illness/injury (acute or chronic), cognitive or physical problems that may limit the ability to perform the necessary activity.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Interested volunteers will receive written information about the study in lay terms and a full description of the inclusion/exclusion criteria. After obtaining informed consent and background information, the potential participants will be screened to confirm eligibility. Once a potential subject has been deemed eligible, the subject will be randomised to the order of experimental conditions. The method for allocation concealment is closed envelopes. The allocation information will be placed in numbered envelopes (1 allocation per envelope) by an independent researcher. After a subject has been enrolled in the study, the study co-ordinators will contact an independent staff member to ask for the sequence of experimental conditions. The independent staff member will keep a log of the date and time the envelope was opened, the envelope number, the initials and gender of the participant and the order of experimental conditions. The study co-ordinator will also keep a record of this information.

Using the randomization schedule, the independent researcher will, after data collection, create a dataset containing outcome, other relevant variables and the random unique code but will not include overt information on the experimental conditions, subject initials, and date of data collection. Data collected under the experimental conditions will be assigned a code (e.g., 0 and 1) unknown to the data analyst and the research team (they would be blinded to the randomization process and condition). Once the data are analysed, the experimental-condition codes will be revealed and the dataset will be checked for errors.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation allocation sequence for will be generated using computer-generated random numbers in a Latin-square experimental design.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Generalized estimating equations will be used to evaluate the differential effects of the trial conditions on the outcomes.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
11/03/2013
Actual
7/05/2013
Date of last participant enrolment
Anticipated
31/08/2013
Actual
30/08/2013
Date of last data collection
Anticipated
Actual
Sample size
Target
19
Accrual to date
Final
19
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 525 0
The Alfred - Prahran
Recruitment postcode(s) [1] 6264 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 286664 0
Government body
Name [1] 286664 0
Swedish Council for Working Life and Social Research
Country [1] 286664 0
Sweden
Primary sponsor type
Charities/Societies/Foundations
Name
Baker IDI Heart and Diabetes Institute
Address
75 Commercial Road, Melbourne, Victoria 3004 (Postal address: PO Box 6492, St Kilda Road Central, Victoria 8008)
Country
Australia
Secondary sponsor category [1] 285442 0
None
Name [1] 285442 0
Address [1] 285442 0
Country [1] 285442 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288733 0
The Alfred Hospital Ethics Committee
Ethics committee address [1] 288733 0
Ethics committee country [1] 288733 0
Australia
Date submitted for ethics approval [1] 288733 0
02/11/2012
Approval date [1] 288733 0
02/01/2013
Ethics approval number [1] 288733 0
531/12

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 37522 0
Prof David Dunstan
Address 37522 0
Baker IDI Heart and Diabetes Institute
Level 4, 99 Commercial Rd, Melbourne, Victoria 3004
Country 37522 0
Australia
Phone 37522 0
+613 8532 1873
Fax 37522 0
+613 8532 1100
Email 37522 0
david.dunstan@bakeridi.edu.au
Contact person for public queries
Name 37523 0
Patrik Wennberg
Address 37523 0
Public Health and Clinical Medicine, Family Medicine Umea University
SE-90187 UMEA
Country 37523 0
Sweden
Phone 37523 0
+46 90 785 14 23
Fax 37523 0
N/A
Email 37523 0
patrik.wennberg@umu.se
Contact person for scientific queries
Name 37524 0
Patrik Wennberg
Address 37524 0
Public Health and Clinical Medicine, Family Medicine Umea University
SE-90187 UMEA
Country 37524 0
Sweden
Phone 37524 0
+46 90 785 14 23
Fax 37524 0
N/A
Email 37524 0
patrik.wennberg@umu.se

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.